JP2024521754A - アルコール使用障害と診断された個体の大量飲酒軽減におけるナルトレキソンのエピジェネティックモデレータの有効性 - Google Patents

アルコール使用障害と診断された個体の大量飲酒軽減におけるナルトレキソンのエピジェネティックモデレータの有効性 Download PDF

Info

Publication number
JP2024521754A
JP2024521754A JP2023572581A JP2023572581A JP2024521754A JP 2024521754 A JP2024521754 A JP 2024521754A JP 2023572581 A JP2023572581 A JP 2023572581A JP 2023572581 A JP2023572581 A JP 2023572581A JP 2024521754 A JP2024521754 A JP 2024521754A
Authority
JP
Japan
Prior art keywords
gene
seq
methylation
oprm1
naltrexone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572581A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022251375A5 (https=
JP2024521754A5 (https=
Inventor
レイモンド エフ アントン，
ジョセフ ピー． シャハト，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Publication of JP2024521754A publication Critical patent/JP2024521754A/ja
Publication of JPWO2022251375A5 publication Critical patent/JPWO2022251375A5/ja
Publication of JP2024521754A5 publication Critical patent/JP2024521754A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023572581A 2021-05-25 2022-05-25 アルコール使用障害と診断された個体の大量飲酒軽減におけるナルトレキソンのエピジェネティックモデレータの有効性 Pending JP2024521754A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192952P 2021-05-25 2021-05-25
US63/192,952 2021-05-25
PCT/US2022/030946 WO2022251375A2 (en) 2021-05-25 2022-05-25 Epigenetic moderators of naltrexone efficacy efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder

Publications (3)

Publication Number Publication Date
JP2024521754A true JP2024521754A (ja) 2024-06-04
JPWO2022251375A5 JPWO2022251375A5 (https=) 2025-06-02
JP2024521754A5 JP2024521754A5 (https=) 2026-04-27

Family

ID=84230385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572581A Pending JP2024521754A (ja) 2021-05-25 2022-05-25 アルコール使用障害と診断された個体の大量飲酒軽減におけるナルトレキソンのエピジェネティックモデレータの有効性

Country Status (5)

Country Link
US (1) US20220389509A1 (https=)
EP (1) EP4326904A4 (https=)
JP (1) JP2024521754A (https=)
CA (1) CA3219484A1 (https=)
WO (1) WO2022251375A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025010067A1 (en) * 2023-07-06 2025-01-09 Smith Genetics Research Llc Treatment of autonomic dysfunction resulting from opioid use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029308A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
US20090307179A1 (en) * 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
US8815779B2 (en) * 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
US20120142543A1 (en) * 2010-11-29 2012-06-07 Kenneth Blum Methods to assess treatment outcomes in Reward Deficiency Syndrome (RDS) behaviors utilizing expression profiling
US20140274763A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to pain treatments
US20180369238A1 (en) * 2017-06-23 2018-12-27 Musc Foundation For Research Development Dopamine agonists in treating alcohol use disorders associated with dopamine receptor activity
US20180371542A1 (en) * 2017-06-26 2018-12-27 Musc Foundation For Research Development Opioid receptor blockade in treating alcohol use disorders

Also Published As

Publication number Publication date
EP4326904A4 (en) 2025-03-26
US20220389509A1 (en) 2022-12-08
CA3219484A1 (en) 2022-12-01
WO2022251375A8 (en) 2024-01-04
WO2022251375A3 (en) 2023-01-05
EP4326904A2 (en) 2024-02-28
WO2022251375A2 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US10202652B2 (en) Methods and compositions of predicting activity of retinoid X receptor modulator
Milani et al. Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation
Li et al. Replication of TCF4 through association and linkage studies in late-onset Fuchs endothelial corneal dystrophy
JP5881420B2 (ja) 自閉症関連遺伝子マーカー
AU2017318669B2 (en) Methods and composition for the prediction of the activity of enzastaurin
CN105431552B (zh) 多组学标记在预测糖尿病中的用途
EP2061910B1 (en) Prognostic method
US20130296182A1 (en) Variability single nucleotide polymorphisms linking stochastic epigenetic variation and common disease
EP2423330A1 (en) Method of prognosing recurrence of prostate cancer
US20220389509A1 (en) Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder
JP2008545390A (ja) 遺伝的多型を用いた肺癌を発達させるリスクの評価方法
WO2010111080A2 (en) Optimized treatment of schizophrenia
WO2008010082A2 (en) Diagnostic method for fibromyalgia (fms) or chronic fatigue syndrome (cfs)
US20050255507A1 (en) Cytogenetically determined diagnosis and prognosis of proliferative disorders
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
KR102650359B1 (ko) 약물 과민반응 진단용 snp 및 이를 이용한 진단 방법
Alrfooh DNA methylation signature: as a potential biomarker for addiction and psychiatric disorders
JP2006296270A (ja) Ｐｒｋａａ２遺伝子多型による２型糖尿病発症素因の検出方法
JP2007517511A (ja) ヒトチオプリンｓ−メチルトランスフェラーゼ欠損に関連するハプロタイプおよび多型
EP4689178A1 (en) Novel assay for phasing of distant genomic loci with zygosity resolution via long-read sequencing hybrid data analysis
WO2011148379A2 (en) Antipsychotic-induced parkinsonism genotypes and methods of using same
WO2009036513A1 (en) Diagnostic and therapeutic protocols
Pal The HLA complex group 9 gene modification study in major psychosis
JP2011239697A (ja) パーキンソン病発症リスクマーカー
EP2917733A2 (en) Methods and compositions for the diagnosis of multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417